Validate a French Nasal Reconstruction FACE-Q quality-of-life questionnaire

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This non-interventional, multicenter project will translate and culturally adapt selected FACE-Q Aesthetics scales into French and then collect patient-reported responses to test reliability and validity. Adults who had nasal excision for skin cancer followed by reconstructive flap surgery or prosthetic rehabilitation between 4 months and 3 years prior will complete the questionnaires at participating centers. A control group of older adults without prior facial surgery will provide comparative normative data. The goal is to produce a standardized French-language instrument that reliably measures appearance, psychosocial well-being, social function, satisfaction with outcomes, and procedure-related adverse effects.

Why it matters

Who can join: the full rules

PATIENTS

Inclusion Criteria

* Age ≥ 18 years
* Patient who has undergone excision of a cutaneous, mucocutaneous, or vestibular nasal cancer with surgical reconstruction using a flap or prosthetic rehabilitation, performed more than 4 months ago, with stable results, and less than 3 years ago
* Patient informed of the study and not opposed to participation

Exclusion Criteria

* Patient under anticoagulant or antiplatelet therapy Non-French-speaking patient
* Patient under legal protection (e.g., guardianship, legal safeguard) or with limited legal capacity
* Patient unlikely to cooperate with the study and/or poor anticipated compliance as judged by the investigator (including psychiatric disorders other than depressive disorder or cognitive impairment)
* Pregnant or breastfeeding woman

CONTROL

Inclusion Criteria

* Age ≥ 65 years
* Subject informed and not opposed to participating in the study
* Subject who has never undergone facial trauma or surgery, and without major comorbidity, defined as follows:
* No heart failure (moderate or severe heart failure, history of heart attack within the last 6 months);
* No severe chronic respiratory disease (no stage III-IV COPD, no prolonged oxygen therapy);
* No uncontrolled diabetes or associated severe complications;
* No active immunosuppressive diseases or high-dose immunosuppressive treatment;
* No unstable or severe facial dermatological conditions;
* No comorbidities seriously affecting quality of life or respiratory function (at the investigator's discretion).

Exclusion Criteria

* Non-English speaking subject
* Subject under guardianship or legal protection, legally incompetent or with limited legal capacity
* Subject unlikely to cooperate in the study and/or anticipated low cooperation by the investigator (particularly those with psychiatric disorders other than depression or cognitive disorders)
* Pregnant or breastfeeding women

Where it's running

• Centre Antoine Lacassagne
  Nice, France Recruiting
• Hopital Novo
  Pontoise, France Recruiting
• HNIA Toulon
  Toulon, France Recruiting
• Institut Gustave Roussy
  Villejuif, France Recruiting
• CHU Caen
  Caen, France Not yet recruiting
• Institut Curie
  Paris, France Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TriAdeno and N-803 vaccine in early prostate cancer on active surveillance

  A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07574541

• PF-08634404 Alone or with chemotherapy in early-stage or locally advanced NSCLC

  This study tests PF-08634404 by itself or with chemotherapy in adults with early-stage or locally advanced non-small cell lung cancer that may be surgically removable or were candidates for additional therapy after initial treatment.

  Recruiting at 28 sites Phase 2 Pfizer · Huntsville, Alabama and 36 other locations · NCT07489066

• Carbon ion radiotherapy for liver cancer that returned after TARE

  This trial will try carbon ion radiotherapy to control liver tumors in people whose hepatocellular carcinoma persisted or came back after TARE.

  Recruiting Yonsei University · Seoul · NCT07252323

• Carbon ion radiotherapy plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma

  This trial will try adding carbon ion radiotherapy to standard atezolizumab‑bevacizumab treatment for adults with advanced hepatocellular carcinoma to see if it controls tumors better and improves survival.

  Recruiting Phase 2 Yonsei University · Seoul · NCT07246668

• Evaluating Pucotenlimab for treating pediatric lymphoepithelioma-like carcinoma

  This study is testing a new treatment combining pucotenlimab with chemotherapy to see if it helps children and teenagers with a rare type of cancer called lymphoepithelioma-like carcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06969534

• Using vorolanib for treating advanced kidney cancer

  This study is testing if the drug vorolanib can help people with advanced kidney cancer live longer when used as a second treatment option.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT06676527

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.